^
Association details:
| Biomarker: | IFNG-L |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Serological markers associated with response and adverse events in patients of esophageal squamous carcinoma with toripalimab combined with nab-paclitaxel and S-1 as neoadjuvant therapy.
Published date:
05/26/2022
Excerpt:
60 patients diagnosed with ESCC and considered propable for surgical treatment were enrolled from October 2019 to September 2020 in the first medical center of Chinese PLA General Hospital and received Toripalimab combined with nab-Paclitaxel and S-1 as neoadjuvant therapy....Patients with IFN-Y-L, LAMP3-L and Gal.1-H at baseline were associated with longer overall survival.
Secondary therapy:
gimeracil/oteracil/tegafur
DOI:
10.1200/JCO.2022.40.16_suppl.e16017
